BiomX (PHGE) AI Stock Analysis

• Market Cap: $3.25M
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: N/A
• EPS Growth: 54.25%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -5.51
• Shares Outstanding: 1,526,640
• 10 Day Avg. Volume: 1,108,900
• 30 Day Avg. Volume: 1,322,820
• PEG Ratio: 0.04
• Price to Book (P/B): 2.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.38
• Enterprise Value/Market Cap: 10.39
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -115.67
• Enterprise Value/Ebitda: -1.13
• 1Y Price Target: $26.00
• Price Target Upside: 1120.66% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: ―

BiomX's overall score is driven by significant financial challenges, including negative revenues and high leverage, which are key risks. However, recent positive trial results and funding announcements provide potential for future growth and improvement.

Positive Factors

Positive Trial Results

The successful Phase 2 trial of BX211 demonstrates BiomX's potential in developing effective phage therapies, enhancing its competitive position in addressing serious bacterial infections.

New Funding

The $12M funding supports the Phase 2b study of BX004, strengthening BiomX's financial position and enabling continued development in the phage therapy market.

Product Development

BiomX's proprietary platform for developing phage therapies positions it well in the microbiome-focused biotech industry, providing a durable competitive advantage.

Negative Factors

Financial Challenges

Ongoing negative revenues and high operating losses indicate financial instability, potentially limiting BiomX's ability to sustain long-term operations without external funding.

High Leverage

High leverage and significant debt levels can restrict BiomX's financial flexibility and increase risk, impacting its ability to invest in growth opportunities.

Regulatory Hold

The FDA hold on BX004's trial, even if temporary, could delay product development timelines and affect BiomX's strategic plans in the cystic fibrosis treatment market.

BiomX Business Overview & Revenue Model

Company Description

BiomX Inc. (PHGE) is a clinical-stage microbiome company that focuses on the discovery and development of bacteriophage-based therapies. These therapies are designed to target and destroy harmful bacteria in the human body, particularly in diseases where the microbiome plays a significant role. The company's core products are aimed at conditions such as acne, inflammatory bowel disease (IBD), and primary sclerosing cholangitis (PSC), leveraging its proprietary microbiome discovery platform to identify and develop phage therapies.

How the Company Makes Money

BiomX primarily makes money through research and development collaborations, grants, and potential future product sales. The company engages in partnerships with pharmaceutical and biotechnology companies to co-develop phage therapies, which can provide upfront payments, milestone payments, and royalties. Additionally, BiomX may receive funding from governmental or non-profit grants to support its research initiatives. As its products progress through clinical trials and potentially reach the market, revenue from sales of approved therapies will become a significant source of income.

BiomX Financial Statement Overview

Summary

BiomX faces significant financial challenges with persistent negative revenues and high operating losses. The balance sheet shows high leverage, and the cash flow statements indicate a reliance on external financing. Despite some improvements in net income and stockholders' equity, the company's overall financial health is strained.

Income Statement

BiomX has consistently reported negative revenues and gross profit over the years, indicating significant challenges in generating income. The company has also faced substantial net losses, although a notable improvement in net income was seen in 2024. The lack of revenue growth and negative margins, such as EBIT and EBITDA, highlight ongoing difficulties in achieving profitability.

Balance Sheet

The company's balance sheet shows high leverage, with a significant amount of total debt relative to equity, resulting in a concerning debt-to-equity ratio. However, the equity ratio indicates that a reasonable portion of the company's assets are financed by equity. Despite recent improvements in stockholders' equity, the overall financial stability remains a concern due to the high liabilities.

Cash Flow

BiomX's cash flow statements reflect ongoing negative free cash flow, indicating cash outflows from operations and investments. While there is a trend of securing financing to support cash needs, this reliance on external funding poses risks. The operating cash flow to net income ratio shows significant cash outflows relative to earnings, underscoring financial pressure.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-292.00K	-1.80M	-871.00K	0.00	0.00	0.00
EBITDA	-29.88M	-13.13M	-22.82M	-23.66M	-32.90M	-29.60M
Net Income	-37.38M	-17.73M	-26.17M	-28.32M	-36.23M	-30.09M
Balance Sheet
Total Assets	26.17M	43.23M	25.03M	45.53M	77.99M	70.36M
Cash, Cash Equivalents and Short-Term Investments	7.91M	17.81M	14.91M	33.33M	62.10M	56.33M
Total Debt	6.58M	9.58M	15.09M	19.36M	20.02M	5.89M
Total Liabilities	15.68M	19.09M	21.95M	24.49M	30.45M	12.89M
Stockholders Equity	10.49M	24.15M	3.08M	21.04M	47.53M	57.47M
Cash Flow
Free Cash Flow	-28.31M	-37.01M	-21.34M	-29.20M	-31.25M	-25.46M
Operating Cash Flow	-28.29M	-36.98M	-21.29M	-29.09M	-27.57M	-24.45M
Investing Cash Flow	106.00K	715.00K	1.95M	-2.11M	16.17M	-10.86M
Financing Cash Flow	11.54M	38.37M	2.90M	292.00K	37.28M	134.00K

BiomX Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHGE, the sentiment is Negative. The current price of 2.13 is below the 20-day moving average (MA) of 3.40, below the 50-day MA of 6.70, and below the 200-day MA of 9.04, indicating a bearish trend. The MACD of -1.35 indicates Negative momentum. The RSI at 31.75 is Neutral, neither overbought nor oversold. The STOCH value of 34.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHGE.

BiomX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHGE	44 Neutral	$3.25M	-0.07	-154.50%	―	―	54.25%
LPCN	43 Neutral	$23.60M	-4.19	-32.92%	―	-44.31%	-34.17%
ADAP	41 Neutral	―	―	-1341.37%	―	-53.61%	-93.14%
CANF	39 Underperform	$24.55M	―	―	―	―	―
IMRN	38 Underperform	$8.06M	-1.61	-49.00%	―	47.17%	26.84%

BiomX Corporate Events

BiomX Announces Positive Phase 2 Trial Results

On March 31, 2025, BiomX Inc. announced positive results from its Phase 2 trial of BX211 for treating Diabetic Foot Osteomyelitis (DFO) associated with Staphylococcus aureus. The trial demonstrated that BX211 was safe, well-tolerated, and produced statistically significant reductions in ulcer size and depth compared to placebo. These findings highlight the potential of phage therapy in addressing serious bacterial infections and reducing the need for amputations in diabetic patients. Following these results, BiomX plans to proceed with a Phase 2/3 trial pending FDA feedback.

BiomX Announces $12M Funding for BX004 Study

On February 25, 2025, BiomX Inc. announced a securities purchase agreement involving a registered direct offering and concurrent private placement, expected to generate approximately $12 million in gross proceeds. The funds will support the Phase 2b clinical study of BX004, a phage cocktail for treating cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, with results anticipated in Q1 2026. The offerings, led by Deerfield Management Company and the Cystic Fibrosis Foundation, are set to close around February 27, 2025, and include a reduction in exercise price for existing warrants. This strategic move aims to advance BiomX’s clinical programs and strengthen its position in the phage therapy market.